| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Mayo Clinic Laboratories takes the lead in designing and optimizing oncology testing based on specific cancer types. Our comprehensive test menu includes evaluations that aid in providing both diagnostic and prognostic information and treatment selection guidance across the full spectrum of malignancies. By offering testing for both acquired and inherited cancers in one place, we serve as the singular source for all cancer testing.
“tests like these assure patients get the best cancer care, as clinicians use these results to determine the best treatment strategies based on the patients tumor profile - It's really that simple.”
Benjamin Kipp, Ph.D., chair of the Division of Laboratory Genetics and Genomics
Our difference
The latest
PACE / State of FL - Register now - May 21, 2025: - This webinar will explore the role of cytology specimens in molecular genetic testing, emphasizing their effectiveness in identifying biomarkers critical for targeted therapies in patients with cancer. Advantages of cytology samples, challenges in specimen adequacy, and how advancements in next-generation sequencing (NGS) have led to improved utilization of cytology samples will be discussed. This discovery has led to enhancing diagnostic accuracy, reducing the need for repeat biopsies, and accelerating personalized cancer treatment, all of which will be highlighted during the webinar.
Genetic alterations in low-risk prostate cancer diagnosed by needle biopsy can identify men that harbor higher-risk cancer in their prostate glands, Mayo Clinic has discovered.
Researchers at the Mayo Clinic Center for Individualized Medicine have discovered that large chromosomal rearrangements present in mesothelioma could make it possible to understand which patients are likely respond better to immunotherapy.
This week’s Research Roundup highlights neoantigenic potential of complex chromosomal rearrangements in mesothelioma.
Researchers at Mayo Clinic have identified three specific gene types that account for a known two- to three-fold increase in myeloma diagnoses among African-Americans. Researchers also demonstrated the ability to study race and racial admixture more accurately using DNA analysis. The findings were published today in Blood Cancer Journal.
This week’s Research Roundup highlights carcinoid heart disease in patients with bronchopulmonary carcinoid.
This week’s Research Roundup highlights the risk of MGUS in relatives of multiple myeloma cases by clinical and tumor characteristics.
This week’s Research Roundup highlights hepatocellular carcinoma detection by plasma methylated DNA through a discovery, phase I pilot, and phase II clinical validation.
This week’s Research Roundup highlights biphenotypic acute leukemia versus myeloid antigen-positive ALL: Clinical relevance of WHO criteria for mixed phenotype acute leukemia.
Clinical studies at the Mayo Clinic have shown that this broad, but tumor-specific, genetic analysis has significant, and sometimes unexpected, clinical impact. The following case studies highlight the importance and clinical utility of these assays in diagnosis, prognosis, and therapy selection.
A research team led by Fergus Couch, Ph.D., a geneticist at Mayo Clinic, has identified specific genes associated with an increased risk for developing triple-negative breast cancer. The team's research was published in the Journal of the National Cancer Institute.
Minetta Liu, M.D., an oncologist at Mayo Clinic, answered a reader's question in Mayo Clinic's "Q and A" about liquid biopsies. The question was, "What is a liquid biopsy? Can it be used in place of a tumor biopsy to find cancer?"
This week’s Research Roundup highlights the association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer.